Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

309
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
309
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

320
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
320
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

61
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
61
Drug Discovery: Overview01:26

Drug Discovery: Overview

12.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.7K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

247
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
247
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

50.2K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assembly of lipid droplet-associated ring structures in hepatitis C virus-infected cells via liquid-liquid phase separation (LLPS) and non-LLPS mechanisms.

Journal of virology·2026
Same author

Metabolomics Approach Identifies Predictive Serum Markers for Hepatocellular Carcinogenesis Following Hepatitis C Virus Elimination.

Cancers·2026
Same author

Identification of an isoquinoline-derived quinazoline hybrid as a transcriptional inhibitor of fatty acid synthase to suppress hepatitis C virus production.

Biochemical and biophysical research communications·2026
Same author

Serum Albumin Levels Are Associated with Total Brain and Hippocampal Volume but Not with White Matter Lesion Volume in Older Japanese Adults Without Cognitive Decline: A Cross-Sectional Study.

Nutrients·2026
Same author

Impact of cardiometabolic criteria on the pathogenesis of MASLD and diagnostic performance of non-invasive tests.

Journal of gastroenterology·2026
Same author

Effects of pemafibrate on liver fibrosis in patients with MASLD and hypertriglyceridemia: A 2-year retrospective observational study using MR elastography.

Journal of clinical lipidology·2026

Related Experiment Video

Updated: Mar 13, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.1K

Advances in drug development for hepatitis C.

Tetsuro Suzuki1, Kenji Nakashima, Takeshi Chida

  • 1Department of Infectious Diseases, Hamamatsu University School of Medicine.

Uirusu
|January 1, 2015
PubMed
Summary

Hepatitis C virus (HCV) treatments have evolved significantly, moving from interferon-based therapies with limited success to highly effective direct-acting antiviral (DAA) combinations. These advancements offer a cure for most patients with chronic HCV infection.

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K

Related Experiment Videos

Last Updated: Mar 13, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.1K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic hepatitis C virus (HCV) infection remains a significant global health challenge.
  • Early interferon-based treatments had limited efficacy and significant side effects.
  • Pegylated interferon (PEG-IFN) and ribavirin (RBV) improved response rates but still required careful patient selection.

Purpose of the Study:

  • To review the evolution of hepatitis C virus (HCV) treatment strategies.
  • To highlight the impact of direct-acting antivirals (DAAs) on treatment outcomes.
  • To discuss the current and future prospects for HCV eradication.

Main Methods:

  • Review of historical and recent advancements in HCV pharmacotherapy.
  • Analysis of sustained virological response (SVR) rates across different treatment eras.
  • Examination of the role of direct-acting antiviral (DAA) classes, including protease inhibitors (PIs), NS5A, and NS5B inhibitors.

Main Results:

  • Initial IFN-based treatments achieved SVR rates around 50%.
  • Addition of first-generation protease inhibitors (PIs) to PEG-IFN/RBV increased SVR rates to approximately 80%.
  • Current IFN-free DAA combination regimens, including NS5A and NS5B inhibitors, achieve SVR rates of 90% or higher.

Conclusions:

  • Direct-acting antivirals (DAAs) have revolutionized hepatitis C virus (HCV) treatment.
  • IFN-free DAA combinations offer high cure rates for the majority of chronic HCV patients.
  • The near-eradication of chronic HCV infection is an achievable public health goal.